Synektik Sa · GPW:SNT

Synektik Sa — Q4 FY2024 Earnings Presentation

23 slides from Synektik Sa's earnings presentation, November 2025

  1. Slide 1: Investor Presentation Q4 FY 2024: Financial results

    SYNEKTIK SA Investor Presentation Q4 FY 2024: Financial results November 2025 Q4 FY 2024 Financial results | Investor presentation 1

  2. Slide 2: Synektik in snapshot

    Synektik in snapshot WIG, mWIG40, Indexes WIGTECH, WIG-Poland ISIN PLSNKTK0001 681m 177m Number of shares 8 529 129 PLN PLN Capitalisation(1) PLN 2.25bn REVENUE FROM SALES, EBITDA FROM CONTINUING Enterprise value(2) PLN 2.21bn Q1-Q4 FY2024 OPERATIONS Q1-Q4 FY2024 P/E(3) 20.7 EV/EBITDA(4) 11.7 Compan

  3. Slide 3: Highlights of Q4 FY2024

    Highlights of Q4 FY2024 Sales of equipment and IT solutions – growing profits, exciting business perspectives  PLN 187.1 million in revenue (excluding intra-group transactions) in Q4 FY 2024, including PLN 83.4 million in recurring revenue (48% YoY growth); PLN 60.1 million EBITDA, EBITDA margin of

  4. Slide 4: Financial performance in Q4 FY2024 (PLN mln)

    Financial performance in Q4 FY2024 (PLN mln) Consolidated revenue  46% increase in total revenue from sales of equipment, IT solutions and Q4 FY2024 199.2 services (excluding intra-group transactions) +41%  4% decrease in revenue of the radiopharmaceuticals segment, Q4 FY2023 141.1 excluding intra

  5. Slide 5: Financial performance in 12M FY2024 (PLN mln)

    Financial performance in 12M FY2024 (PLN mln)  9% increase in total revenue from sales of equipment, IT solutions and Consolidated revenue Q1-Q4 services (excluding intra-group transactions) 681.3 FY2024 +9%  12% increase in revenue of the radiopharmaceuticals segment, FY2023 624.1 excluding intra

  6. Slide 6: Group's adjusted EBITDA in FY 2021-2024

    Group’s adjusted* EBITDA in FY 2021-2024 Adjusted* EBITDA EBITDA growth driven by: (PLNm) 54.6 52.7 50.5  Growing scale of recurring sales in both 41.6 segments, characterized by attractive 29.8 30.4 31.7 31.7 33.8 margins 24.9 24.9 13.3  Increase in sales of equipment used in 10.9 5.5 6.2 7.1 the

  7. Slide 7: Group's recurring sales in FY 2021-2024

    Group’s recurring sales in FY 2021-2024 Recurring revenue for past 4 quarters Dynamic growth of recurring revenue (PLNm) Drivers: 35.8  Dynamically increasing demand for consumable 35.0 parts and accessories for therapy equipment sold by the Synektik Group 33.2 Revenue from sales of radiopharmaceut

  8. Slide 8: Selected financial data

    Selected financial data PLN 000s Q4 FY 2024 Q4 FY 2023 Q1-Q4 FY 2024 FY 2023 Sales revenue 199 237 141 144 681 297 624 122  Cash surplus over financial liabilities amounting to EBIT* 49 528 29 249 157 024 126 817 nearly PLN 44 million as of September 30, 2025 EBIT margin* 24,9% 20,7% 23,0% 20,3% EB

  9. Slide 9: Medical equipment and IT solutions

    SYNEKTIK SA Medical equipment and IT solutions Q4 FY 2024 Financial results | Investor Q3 Investor presentation presentation 9

  10. Slide 10: Medical equipment and IT solutions: Key information

    Medical equipment and IT solutions Key information Synektik is a leading provider of medical equipment and IT solutions used in radiology, oncology, cardiology and neurology Core areas:  Sale of medical equipment from several leading manufacturers, used in radiology, therapy and nuclear medicine 

  11. Slide 11: Medical equipment and IT solutions: Financial results

    Medical equipment and IT solutions Financial results (PLN million) Growing business profitabiity 630.8 579.1  46% increase in sales (year-over-year) in Q4 FY 2024, up to PLN 187.1 million  70% increase in EBITDA in Q4 FY 2024, up to PLN 60.1 million 185.6 143.6  PLN 630.8 million in revenue in Q1

  12. Slide 12: Medical equipment and IT solutions: Consistent business development

    Medical equipment and IT solutions Consistent business development Segment revenue* (PLN million) +45% CAGR  45% revenue CAGR over the last 5 years, stimulated by expansion in the sale of innovative therapeutic and diagnostic products, with robotic solutions at 579.1 630.8 the forefront 410.4 96.9

  13. Slide 13: Promising prospects for FY 2025

    Medical equipment and IT solutions Promising prospects for FY 2025 Sales of medical equipment, orders for implementation and active offers (in PLN million)  Secured orders worth PLN 391 million in Q1-Q4 FY 2024  The value of active offers as of the end of Septmeber 2025 is PLN 198.7 million, compa

  14. Slide 14: Commercialization of da Vinci system

    Medical equipment and IT solutions Commercialization of da Vinci system Da Vinci assisted surgical procedures in Poland, Czech Republic and 10000 Slovakia (number) 113 9000  Approximately 5.6 k surgeries with the assistance of da Vinci in Q4 FY 2024 in Poland (up 52% y/y), 19.8 k in the last 4 quar

  15. Slide 15: Da Vinci systems serviced by Synektik

    Medical equipment and IT solutions Gdynia Da Vinci serviced by GK Synektik Słupsk Gdańsk Grudziądz Olsztyn 113 75 Szczecin Białystok Bydgoszcz Toruń Wieliszew Biała Podlaska Grodzisk Da Vinci systems serviced da Vinci systems Gorzów Wlkp. Maz. by GK Synektik in Poland* Poznań Warszawa Siedlce Zielon

  16. Slide 16: Radiopharmaceuticals

    SYNEKTIK SA Radiopharmaceuticals Q4 FY 2024 Financial results | Investor presentation 16

  17. Slide 17: Radiopharmaceuticals: Key information

    Radiopharmaceuticals Key information  Synektik is the largest producer and supplier of PET/CT radiopharmaceuticals in Poland 55+ Number of 3 Production sites together employees with R&D Centre  Major producer of special radiopharmaceuticals Location of cyclotrons for the production of radiopharmac

  18. Slide 18: Radiopharmaceuticals: Financial results

    Radiopharmaceuticals Financial results (PLN million) Growing revenues, revenue diversification 50.5 45.1  PLN 12.2 million in revenue in Q4 FY 2024, compared to PLN 12.7 million the year earlier 16.3 16.1  PLN 6.1 million in basic marker sales, down 1% y/y  37% growth in special marker sales, to

  19. Slide 19: Radiopharmaceuticals: Stable business growth

    Radiopharmaceuticals Stable business growth Segment revenue* (PLN million) +12% CAGR  12% revenue CAGR over the last 5 years, driven by increased demand for radiotracers and sales price updates 50.5 45.1 36.5 28.5 27.7 28.9  14% segment EBITDA CAGR  Increase in segment EBITDA margin over the last

  20. Slide 20: Cardiotracer

    SYNEKTIK SA Cardiotracer Q4 FY 2024 Financial results | Investor presentation 20

  21. Slide 21: Synektik S.A. spin-off plan

    Synektik S.A. spin-off plan  On July 23, 2025, the management boards of Synektik SA and Syn2bio SA agreed on and adopted a plan to divide Synektik SA into two independent publicly listed entities: Cardiac-tracer  To Syn2bio SA, in exchange for shares of a new issue, a part of Synektik SA’s busines

  22. Slide 22: Q&A SESSION

    SYNEKTIK SA Q&A SESSION Q4 FY 2024 Financial results | Investor presentation 22

  23. Slide 23: Thank you!

    Cezary Kozanecki Thank you! President of the Management Board, CEO ckozanecki@synektik.com.pl Dariusz Korecki Vice-President of the Management Board, CFO dkorecki@synektik.com.pl

Synektik — Q4 FY2024 Earnings Presentation on 6ix